IZEA +50% on the release of artificial intelligence CurationEngine.
OTC:ARDM +36% as FDA accepts marketing application for Linhaliq under Priority Review.
GPC +10% on acquisition of Alliance Automotive Group.
IDXG +11% on the launch of a new lung cancer test, MVPdX.
NLNK +8% on teaming up with AstraZeneca to evaluate indoximod/durvalumab combo in pancreatic cancer.
ICPT +6% on Ocaliva-related deaths in certain PBC patients due to failure to follow recommended dosing regimen.